NeuroMetrix Announces That Quell Will Be Featured in the Target Open House

WALTHAM, Mass.--(BUSINESS WIRE)--

NeuroMetrix, Inc. NURO announced today that Quell^® will be featured in the Target Open House in San Francisco.

"We are delighted that Target has added Quell to their Open House concept," said Frank McGillin, SVP and General Manager, Consumer of NeuroMetrix. "Consumers are showing a tremendous interest in connected products, particularly around health and wellness. The Open House provides a great opportunity for consumers to experience Quell in an interactive space."

Quell is FDA cleared and designed for the millions of people suffering from chronic pain. The advanced wearable technology delivers 100% drug free relief and is available without a prescription. Quell can be used during the day while active, and at night while sleeping. Quell gives users the option to start, stop, and adjust therapy discreetly via their smartphone. It also provides therapy utilization and advanced sleep tracking. Quell is available at select healthcare professionals and retailers. To find a Quell retailer, visit the Store Locator at QuellRelief.com.

The Target Open House is part retail space, part lab, part meeting venue for the connected home tech community. The 3,500 square-foot space features a range of IoT innovations in a transparent, acrylic "house" where guests will experience vignettes that demonstrate in unprecedented ways how multiple connected devices can work together to create real-life solutions. The Target Open House is located at 115 4th Street, San Francisco, CA 94103.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain and diabetes. The company's lead product is Quell^®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck^®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160825005218/en/